{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T09:17:20Z","timestamp":1790414240719,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1016\/j.ahj.2009.11.025","type":"journal-article","created":{"date-parts":[[2010,3,9]],"date-time":"2010-03-09T04:46:51Z","timestamp":1268110011000},"page":"340-347.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":358,"title":["Rivaroxaban\u2014Once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and Design of the ROCKET AF study"],"prefix":"10.1016","volume":"159","clinical-trial-number":[{"clinical-trial-number":"nct00403767","registry":"10.18810\/clinical-trials-gov"}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2009.11.025_bib1","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/archinte.1995.00430050045005","article-title":"Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications","volume":"155","author":"Feinberg","year":"1995","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ahj.2009.11.025_bib2","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","article-title":"Prevalence of Diagnosed Atrial Fibrillation in Adults: National Implications for Rhythm Management and Stroke Prevention: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study","volume":"285","author":"Go","year":"2001","journal-title":"JAMA"},{"issue":"6 Suppl","key":"10.1016\/j.ahj.2009.11.025_bib3","doi-asserted-by":"crossref","first-page":"546S","DOI":"10.1378\/chest.08-0678","article-title":"Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Singer","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.ahj.2009.11.025_bib4","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/0002-9149(94)90363-8","article-title":"Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study)","volume":"74","author":"Furberg","year":"1994","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2009.11.025_bib5","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/0002-8703(83)90208-9","article-title":"Coronary heart disease and atrial fibrillation: the Framingham Study","volume":"106","author":"Kannel","year":"1983","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2009.11.025_bib6","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the Framingham Study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"key":"10.1016\/j.ahj.2009.11.025_bib7","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/archinte.1987.00370090041008","article-title":"Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study.","volume":"147","author":"Wolf","year":"1987","journal-title":"Arch Intern Med."},{"key":"10.1016\/j.ahj.2009.11.025_bib8","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1161\/01.STR.27.10.1760","article-title":"Stroke severity in atrial fibrillation. The Framingham Study","volume":"27","author":"Lin","year":"1996","journal-title":"Stroke"},{"key":"10.1016\/j.ahj.2009.11.025_bib9","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1136\/bmj.311.7016.1361","article-title":"ABC of atrial fibrillation. History, epidemiology, and importance of atrial fibrillation","volume":"311","author":"Lip","year":"1995","journal-title":"BMJ"},{"issue":"Suppl 3","key":"10.1016\/j.ahj.2009.11.025_bib10","doi-asserted-by":"crossref","first-page":"SIII1","DOI":"10.1016\/S0140-6736(98)90086-1","article-title":"Epidemiology of stroke","volume":"352","author":"Warlow","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2009.11.025_bib11","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2009.11.025_bib12","first-page":"2066","article-title":"Effect of clopidogrel added to aspirin in patients with atrial fibrillation","volume":"14","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2009.11.025_bib13","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","article-title":"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial","volume":"367","author":"Connolly","year":"2006","journal-title":"Lancet"},{"issue":"1 Suppl","key":"10.1016\/j.ahj.2009.11.025_bib14","doi-asserted-by":"crossref","first-page":"8S","DOI":"10.1378\/chest.119.1_suppl.8S","article-title":"Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range","volume":"119","author":"Hirsh","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.ahj.2009.11.025_bib15","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1001\/jama.293.6.690","article-title":"Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial","volume":"293","author":"Albers","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2009.11.025_bib16","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archinte.167.3.239","article-title":"Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V","volume":"167","author":"White","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ahj.2009.11.025_bib17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11239-006-9022-7","article-title":"Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM)","volume":"23","author":"Ansell","year":"2007","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.ahj.2009.11.025_bib18","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11239-006-5580-y","article-title":"Worldwide management of oral anticoagulant therapy: the ISAM study","volume":"21","author":"Pengo","year":"2006","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.ahj.2009.11.025_bib19","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1368-5031.2006.00790.x","article-title":"Patterns of use of antithrombotic therapy and quality of anticoagulation among patients with non-valvular atrial fibrillation in clinical practice","volume":"60","author":"Boulanger","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ahj.2009.11.025_bib20","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1161\/CIRCULATIONAHA.106.653048","article-title":"Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation","volume":"115","author":"Hylek","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2009.11.025_bib21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/archinte.160.1.41","article-title":"Why do patients with atrial fibrillation not receive warfarin?","volume":"160","author":"Bungard","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ahj.2009.11.025_bib22","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00228-005-0043-5","article-title":"Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939\u2014an oral, direct Factor Xa inhibitor\u2014after multiple dosing in healthy male subjects","volume":"61","author":"Kubitza","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ahj.2009.11.025_bib23","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1124\/dmd.108.025569","article-title":"Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans","volume":"37","author":"Weinz","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ahj.2009.11.025_bib24","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1177\/0091270006292127","article-title":"Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Rivaroxaban\u2014an Oral, Direct Factor Xa Inhibitor\u2014Are Not Affected by Aspirin","volume":"46","author":"Kubitza","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ahj.2009.11.025_bib25","first-page":"702","article-title":"No interaction between the novel, oral direct Factor Xa inhibitor BAY 59-7939 and digoxin","volume":"46","author":"Kubitza","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ahj.2009.11.025_bib26","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1365-2125.2006.02776.x","article-title":"Rivaroxaban (BAY 59-7939)\u2014an oral, direct Factor Xa inhibitor\u2014has no clinically relevant interaction with naproxen","volume":"63","author":"Kubitza","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ahj.2009.11.025_bib27","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1177\/0091270006286904","article-title":"Effect of Food, an Antacid, and the H2 Antagonist Ranitidine on the Absorption of BAY 59-7939 (Rivaroxaban), an Oral, Direct Factor Xa Inhibitor, in Healthy Subjects","volume":"46","author":"Kubitza","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ahj.2009.11.025_bib28","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty","volume":"358","author":"Eriksson","year":"2008","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ahj.2009.11.025_bib29","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","article-title":"Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial","volume":"372","author":"Kakkar","year":"2008","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.ahj.2009.11.025_bib30","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1056\/NEJMoa076016","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty","volume":"358","author":"Lassen","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2009.11.025_bib31","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(09)60734-0","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial","volume":"16","author":"Turpie","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2009.11.025_bib32","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/CIRCULATIONAHA.106.668020","article-title":"Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study","volume":"116","author":"Agnelli","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2009.11.025_bib33","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2008-05-160143","article-title":"A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study.","volume":"112","author":"Buller","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ahj.2009.11.025_bib34","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jacc.2006.07.009","volume":"48","author":"Fuster","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2009.11.025_bib35","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/sim.3462","article-title":"Comparison of several testing strategies for combination drug efficacy trials based on the closure principle","volume":"28","author":"Soulakova","year":"2009","journal-title":"Stat Med"},{"key":"10.1016\/j.ahj.2009.11.025_bib36","doi-asserted-by":"crossref","first-page":"455","DOI":"10.7326\/0003-4819-133-6-200009190-00014","article-title":"Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues","volume":"133","author":"Temple","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2009.11.025_bib37","doi-asserted-by":"crossref","first-page":"464","DOI":"10.7326\/0003-4819-133-6-200009190-00015","article-title":"Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases","volume":"133","author":"Ellenberg","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2009.11.025_bib38","doi-asserted-by":"crossref","first-page":"492","DOI":"10.7326\/0003-4819-131-7-199910050-00003","article-title":"Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis","volume":"131","author":"Hart","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2009.11.025_bib39","unstructured":"Guideline IHT. Available at: http:\/\/www.ich.org\/cache\/compo\/475-272-1.html. Last accessed June, 2009."}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870309009466?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870309009466?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:39:51Z","timestamp":1757569191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870309009466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S0002870309009466"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2009.11.025","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rivaroxaban\u2014Once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and Design of the ROCKET AF study","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2009.11.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}